


RECEIVED

TECH. CENTER 1600/2300

JUN 25 2001

Sheet 1 (A) of 12



SUBSTITUTE FORM PTO-449 (MODIFIED)  
 U.S. DEPARTMENT OF COMMERCE  
 PATENT AND TRADEMARK OFFICE  
 INFORMATION DISCLOSURE  
 STATEMENT BY APPLICANT  
 (37 CFR 1.98(b))  
 (Use several sheets if necessary)

ATTY. DOCKET NO.  
 RENAS/03  
 SERIAL NO.  
 09/838,968  
 APPLICANT  
 Michael B. Foster  
 FILING DATE  
 April 20, 2001  
 GROUP  
 Not Assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
CMK	A.A	5 8 5 5 9 2 0	01/1999	Chien			
	A.B						
	A.C						
	A.D						
	A.E						
	A.F						
	A.G						
	A.H						
	A.I						
	A.J						
	A.K						

FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS

		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
	A.L						
	A.M						
	A.N						
	A.O						
	A.P						
	A.Q						

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

CMK	A.R	Scientific program and abstracts, <u>Consultants Conference on Adult Growth Hormone Deficiency</u> , Genentech, Inc., San Francisco, CA, 1998, 6-50.
	A.S	Amato et al., <u>Body composition, bone metabolism, and heart structure and function in growth hormone (GH)-deficient adults before and after GH replacement therapy at low doses</u> , Journal of Clinical Endocrinology and Metabolism, Vol. 77, No. 6, 1993, 1671-1676.
CMK	A.T	Andrews, <u>Forever young</u> , Smart Money, 2000, 127-132.

EXAMINER *Chien* DATE CONSIDERED *3/5/02*


EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered. Include a copy of this form with next communication to applicant.

RECEIVED

TECH. CENTER 1600/2900

JUN 25 2001

Sheet 2 (B) 12



SUBSTITUTE FORM PTO-449  
(MODIFIED)

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(Use several sheets if necessary)

(37 CFR 1.98(b))

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.  
RENAS/03

SERIAL NO.

APPLICANT  
Michael B. Foster

FILING DATE  
April 20, 2001

GROUP

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	B.A						
	B.B						
	B.C						
	B.D						
	B.E						
	B.F						
	B.G						
	B.H						
	B.I						
	B.J						
	B.K						

FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS


		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
	B.L						
	B.M						
	B.N						
	B.O						
	B.P						
	B.Q						

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

CMK	B.R	Attanasio et al., <u>Adult growth hormone (GH)-deficient patients demonstrate heterogeneity between childhood onset and adult onset before and during human GH treatment</u> , Journal of Clinical Endocrinology and Metabolism, Vol. 82, No. 1, 1997, 82-88.
	B.S	Bates et al., <u>The effect of hypopituitarism on life expectancy</u> , Journal of Clinical Endocrinology and Metabolism, Vol. 81, No. 3, 1996, 1169-1172.
CMK	B.T	Bengtsson, <u>Efficacy of growth hormone-replacement therapy: quality of life and performance</u> , The Endocrinologist, Vol. 8, No. 6, Supp1, Lippincott Williams & Wilkins, 1998, 31S-35S.

EXAMINER 	DATE CONSIDERED 3/5/02
--------------	---------------------------

EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered. Include a copy of this form with next communication to applicant.

SUBSTITUTE FORM PTO-1449 (MODIFIED)		 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. RENAS/03		SERIAL NO.	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (Use several sheets if necessary)				APPLICANT Michael B. Foster		GROUP	
(37 CFR 1.98(b))				FILING DATE April 20, 2001			

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL	PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
	C.A.						
	C.B.						
	C.C.						
	C.D.						
	C.E.						
	C.F.						
	C.G.						
	C.H.						
	C.I.						
	C.J.						
	C.K.						


  

FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS							
DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)		
	C.L.						
	C.M.						
	C.N.						
	C.O.						
	C.P.						
	C.Q.						

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)		
CMK	C.R	Bengtsson, <u>The consequences of growth hormone deficiency in adults</u> , Acta Endocrinologica, Vol. 128, Supp 2, 1993, 2-5.
/	C.S	Bengtsson et al., <u>Treatment of adults with growth hormone (GH) deficiency with recombinant human GH</u> , Journal of Clinical Endocrinology and Metabolism, Vol. 76, No. 2, 1993, 309-317.
CMK	C.T	Biller, <u>Efficacy of growth hormone-replacement therapy: body composition and bone density</u> , The Endocrinologist, Vol. 8, No. 6, Supp 1, 1998, 15S-21S.

EXAMINER 	DATE CONSIDERED 3/5/02
---	---------------------------

EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered. Include a copy of this form with next communication to applicant.

SUBSTITUTE FORM PTO-1449  
(MODIFIED)

JUN 04 2001

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
RENAS/03

SERIAL NO.

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANTAPPLICANT  
Michael B. Foster

(37 CFR 1.98(b))

(Use several sheets if necessary)

FILING DATE  
April 20, 2001

GROUP

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	D.A						
	D.B						
	D.C						
	D.D						
	D.E						
	D.F						
	D.G						
	D.H						
	D.I						
	D.J						
	D.K						

## FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS

		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
	D.L						
	D.M						
	D.N						
	D.O						
	D.P						
	D.Q						

## OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

CMK	D.R	Blethen, <u>Dosing, monitoring, and safety of growth hormone-replacement therapy in adults with growth hormone deficiency</u> , The Endocrinologist, Vol. 8, No. 6, Supp 1, 1998, 36S-40S.
/	D.S	Brody, <u>Restoring ebbing hormones may slow aging</u> , The New York Times, July 18, 1995, late edition, Sec. C, Page 1, Col. 1, 2-10.
CMK	D.T	Carter, <u>Effect of anabolic hormones and insulin-like growth factor-I on muscle mass and strength in elderly persons</u> , Clinics in Geriatric Medicine, Vol. 11, No. 4, 1995, 735-748.

EXAMINER

DATE CONSIDERED

3/5/02

EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered. Include a copy of this form with next communication to applicant.

SUBSTITUTE FORM PTO-1449  
(MODIFIED)

JUN 04 2001

INFORMATION DISCLOSURE  
STATE TRADEMARK APPLICANT

(Use several sheets if necessary)

(37 CFR 1.98(b))

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
RENAS/03

SERIAL NO.

APPLICANT  
Michael B. FosterFILING DATE  
April 20, 2001

GROUP

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	E.A						
	E.B						
	E.C						
	E.D						
	E.E						
	E.F						
	E.G						
	E.H						
	E.I						
	E.J						
	E.K						

## FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS

		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
	E.L						
	E.M						
	E.N						
	E.O						
	E.P						
	E.Q						

## OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)


CMK	E.R	Cuneo et al., <u>Growth hormone treatment improves serum lipids and lipoproteins in adults with growth hormone deficiency</u> , Metabolism, Vol. 42, No. 12, 1993, 1519-1523.
I	E.S	Cuneo, <u>Efficacy of growth hormone-replacement therapy: lipid and cardiovascular effects.</u> , The Endocrinologist, Vol. 8, No. 6, Supp 1, 1995, 22S-30S.
CMK	E.T	de Boer et al., <u>Serum lipid levels in growth hormone-deficient men</u> , Metabolism, Vol. 43, No. 2, 1994, 199-203.

EXAMINER

DATE CONSIDERED

3/5/02

EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered. Include a copy of this form with next communication to applicant.

SUBSTITUTE FORM PTO-1449  
(MODIFIED)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
RENAS/03

SERIAL NO.

APPLICANT  
Michael B. FosterFILING DATE  
April 20, 2001

GROUP

(37 CFR 1.98(b))

(Use several sheets if necessary)

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	F.A						
	F.B						
	F.C						
	F.D						
	F.E						
	F.F						
	F.G						
	F.H						
	F.I						
	F.J						
	F.K						

## FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS

		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
	F.L						
	F.M						
	F.N						
	F.O						
	F.P						
	F.Q						

## OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)


CMK	F.R	Eden et al., <u>Growth hormone treatment of growth hormone-deficient adults results in a marked increase in Lp(a) and HDL cholesterol concentrations</u> , Arteriosclerosis and Thrombosis, Vol. 13, No. 2, 1993, 296-301.
/	F.S	Ho and Hoffman, <u>Aging and Growth Hormone</u> , Horm Res, Vol. 40, 1993, 80-86.
CMK	F.T	Hoffman et al., <u>Adults with growth hormone deficiency have abnormal body composition but normal energy metabolism</u> , Journal of Clinical Endocrinology and Metabolism, Vol. 80, No. 1, 1995, 72-77.

EXAMINER

DATE CONSIDERED

3/5/02

EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered. Include a copy of this form with next communication to applicant.

SUBSTITUTE FORM PTO-1449  
(MODIFIED)

JUN 04 2001

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
RENAS/03

SERIAL NO.

INFORMATION DISCLOSURE  
STATEMENT OF APPLICANTAPPLICANT  
Michael B. FosterFILING DATE  
April 20, 2001

GROUP

(37 CFR 1.98(b))

(Use several sheets if necessary)

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	G.A						
	G.B						
	G.C						
	G.D						
	G.E						
	G.F						
	G.G						
	G.H						
	G.I						
	G.J						
	G.K						

## FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS

		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
	G.L						
	G.M						
	G.N						
	G.O						
	G.P						
	G.Q						

## OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

CMK	G.R	Holloway et al., <u>Effects of recombinant human growth hormone on metabolic indices, body composition, and bone turnover in healthy elderly women</u> , Journal of Clinical Endocrinology and Metabolism, 1994, 470-479.
/	G.S	Johansson et al., <u>Treatment of growth hormone-deficient adults with recombinant human growth hormone increases the concentration of growth hormone in the cerebrospinal fluid and affects neurotransmitters</u> , Neuroendocrinology, Vol. 61, 1995, 57-66.
CMK	G.T	Kirkland et al., <u>Physician and clinic charges for diagnosing growth hormone deficiency</u> , J. Pediatrics, 1996, S61-S62.

EXAMINER

DATE CONSIDERED

3/5/02

EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered. Include a copy of this form with next communication to applicant.

SUBSTITUTE FORM PTO-1449 (MODIFIED)  INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (Use several sheets if necessary)  (37 CFR 1.98(b))	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. RENAS/03	SERIAL NO.
	APPLICANT Michael B. Foster		
	FILING DATE April 20, 2001	GROUP	

## U.S. PATENT DOCUMENTS


EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	H.A						
	H.B						
	H.C						
	H.D						
	H.E						
	H.F						
	H.G						
	H.H						
	H.I						
	H.J						
	H.K						

## FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS

		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
	H.L						
	H.M						
	H.N						
	H.O						
	H.P						
	H.Q						

## OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

CMK	H.R	Kleinberg and Melmed, <u>The adult growth hormone deficiency syndrome: signs, symptoms, and diagnosis</u> , The Endocrinologist, Vol. 8, No. 6, Supp 1, 1998, 8S-14S.
I	H.S	Lieberman and Hoffman, <u>Growth hormone deficiency in adults: characteristics and response to growth hormone replacement</u> , J. Pediatrics, Vol. 128, No. 5, Part 2, 1996, S58-S60.
CMK	H.T	Meling and Nylen, <u>Growth hormone deficiency in adults: a review</u> , The American Journal of the Medical Sciences, Vol. 311, No. 4, 1996, 153-166.

EXAMINER 	DATE CONSIDERED 3/5/02
---	---------------------------

EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered. Include a copy of this form with next communication to applicant.



RECEIVED

Sheet 9 (I) 12

SUBSTITUTE FORM PTO-1449  
(MODIFIED)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
RENAS/03SERIAL NO.  
09/838,968INFORMATION DISCLOSURE  
STATEMENT BY APPLICANTAPPLICANT  
Michael B. FosterFILING DATE  
April 20, 2001GROUP  
Not Assigned

(37 CFR 1.98(b))

(Use several sheets if necessary)

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	I.A						
	I.B						
	I.C						
	I.D						
	I.E						
	I.F						
	I.G						
	I.H						
	I.I						
	I.J						
	I.K						

## FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS

		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
	I.L						
	I.M						
	I.N						
	I.O						
	I.P						
	I.Q						

## OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

CMK	I.R	Drake and Monson, <u>Individual susceptibility and GH dosing regimen in adults in Growth Hormone Therapy</u> , JohnP. Monson, Ed., Blackwell Science Ltd., Osney Mead, Oxford, 1999.
/	I.S	Nass et al., <u>Effect of growth hormone (hGH) replacement therapy on physical work capacity and cardiac and pulmonary function in patients with hGH deficiency acquired in adulthood</u> , Journal of Clinical Endocrinology and Metabolism, Vol. 80, No. 2, 1995, 552-557.
CMK	I.T	Rosen et al., <u>Decreased psychological well-being in adult patients with growth hormone deficiency</u> , Clinical Endocrinology, Vol. 40, 1994, 111-116.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Substitute Disclosure Form (PTO-1449)

SUBSTITUTE FORM PTO-1449  
(MODIFIED)INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(Use several sheets if necessary)

(37 CFR 1.98(b))

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
RENAS/03

SERIAL NO.

APPLICANT  
Michael B. FosterFILING DATE  
April 20, 2001

GROUP

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	J.A						
	J.B						
	J.C						
	J.D						
	J.E						
	J.F						
	J.G						
	J.H						
	J.I						
	J.J						
	J.K						

## FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS

		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
	J.L						
	J.M						
	J.N						
	J.O						
	J.P						
	J.Q						

## OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)


CMK	J.R	Rosen et al., <u>Cardiovascular risk factors in adult patients with growth hormone deficiency</u> , Acta Endocrinologica, Vol. 129, 1993, 195-200.
	J.S	Rosen and Bengtsson, <u>Premature mortality due to cardiovascular disease in hypopituitarism</u> , The Lancet, Vol. 336, 1990, 285-288.
CMK	J.T	Rudman, M.D. et al., <u>Effects of human growth hormone in men over 60 years old</u> , The New England Journal of Medicine, Vol. 323, No. 1, 1990, 1-6.

EXAMINER

DATE CONSIDERED

3/5/02

EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered. Include a copy of this form with next communication to applicant.

SUBSTITUTE FORM PTO-1449  
(MODIFIED)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
RENAS/03

SERIAL NO.

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANTAPPLICANT  
Michael B. Foster

(37 CFR 1.98(b))

(Use several sheets if necessary)

FILING DATE  
April 20, 2001

GROUP

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	K.A						
	K.B						
	K.C						
	K.D						
	K.E						
	K.F						
	K.G						
	K.H						
	K.I						
	K.J						
	K.K						

## FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS

		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
	K.L						
	K.M						
	K.N						
	K.O						
	K.P						
	K.Q						

## OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

CMK	K.R	Russell-Jones et al., <u>The effect of growth hormone replacement on serum lipids, lipoproteins, apolipoproteins and cholesterol precursors in adult growth hormone deficient patients</u> , Clinical Endocrinology, Vol. 41, 1994, 345-350.
/	K.S	Salomon et al., <u>The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency</u> , The New England Journal of Medicine, Vol. 321, No. 26, 1989, 1797-1803.
CMK	K.T	Schwartz, <u>Tropic factor supplementation: effect on the age-associated changes in body composition</u> , The Journal of Gerontology, Series A, Vol. 50A, 1995, 151-156.

EXAMINER

CMK

DATE CONSIDERED

3/5/02

EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered. Include a copy of this form with next communication to applicant.

SUBSTITUTE FORM PTO-1449  
(MODIFIED)JUN 04 2001  
U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
RENAS/03

SERIAL NO.

INFORMATION DISCLOSURE  
STATEMENT OF THE APPLICANTAPPLICANT  
Michael B. Foster

(37 CFR 1.98(b))

(Use several sheets if necessary)

FILING DATE  
April 20, 2001

GROUP

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	L.A.						
	L.B.						
	L.C.						
	L.D.						
	L.E.						
	L.F.						
	L.G.						
	L.H.						
	L.I.						
	L.J.						
	L.K.						

## FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS

		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANSLATION (YES/NO)
	L.L.						
	L.M.						
	L.N.						
	L.O.						
	L.P.						
	L.Q.						

## OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

CHK	L.R.	Shore et al., <u>Bone mineral status in growth hormone deficiency</u> , J. Pediatrics, Vol. 96, No. 3, part 1, 1980, 393-396.
CHK	L.S.	Sönksen and Weissberger, <u>Growth hormone deficiency in adults</u> , Growth Genetics and Hormones, Vol. 14, No. 3, 1998, 41-48.
	L.T.	

EXAMINER

DATE CONSIDERED

3/5/02

EXAMINER: Initial if citation considered, whether or not in conformance. Draw line through citation only if not in conformance and not considered. Include a copy of this form with next communication to applicant.